Navigation Links
ThromboGenics Announces Half Year Results 2008
Date:8/28/2008

to R&D expenses related to the Company's increasing number of

clinical development programs. The net profit over the reported period

amounts to EUR 18.0 million against a loss of EUR16.0 million over the

full year 2007.

- The Company expects to see an increase in its operating

expenses in the second half of the year as it starts to invest in the

Phase III program for microplasmin in back of the eye disease

- As of June 30, 2008, ThromboGenics had EUR 40.4 million in

cash and cash equivalents. This compares to EUR49.3 million on June 30,

2007 and EUR 46.1 million on December 31, 2007. This cash position does

not yet include the upfront payment from Roche of EUR 30 million that

was only received in July 2008.

Prof. Desire Collen, CEO and Chairman of ThromboGenics, commenting on today's announcement, said: "ThromboGenics has made excellent progress in the first half of 2008. We have not only seen very promising clinical data with our lead product, microplasmin, but also signed a significant co-development deal with Roche for our unique anti-cancer agent, TB-403. The ability of microplasmin to resolve certain back of the eye conditions coupled with the financial benefits which our alliance with Roche brings, means we are now well-positioned to advance microplasmin into its Phase III clinical development program. As ThromboGenics continues to transform itself into a late-stage development company, I am confident that we have all the tools available to ensure our corporate success."

For the full report of these results please go to http://www.thrombogenics.com

About ThromboGenics

ThromboGenics is a biotechnology company focused on discovery and development of biopharmaceuticals for the treatment of eye disease, vascular disease and cancer. The Company has several programs in Phase II clinical development including microp
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
2. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
3. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
4. ThromboGenics N.V. - Business Update
5. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
6. ThromboGenics Announces 2007 Full Year Results
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
9. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
10. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
11. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... EL SEGUNDO, Calif. , July 30, 2014 ... prime contractor on the Fully Integrated Lifecycle Mission ... Aeronautics and Space Administration (NASA). Under the terms ... to Ames Research Center at Moffett Field, Calif. ... management support for bioscience flight development projects on ...
(Date:7/30/2014)... BCC Research ( http://www.bccresearch.com ) reveals ... in Industrial Applications , the global market for industrial ... by 2018, registering a five-year compound annual growth rate ... recorded in the detergent enzyme segment with a CAGR ... has influenced almost every sector of industrial activity, ranging ...
(Date:7/30/2014)... July 30, 2014  Orexigen Therapeutics, Inc. (Nasdaq: ... Day 180 List of Outstanding Issues (LOI) from the ... Use (CHMP) for the NB32 Marketing Authorization Application (MAA). ... an investigational drug candidate being evaluated for weight loss. ... 120 time point were adequately addressed by the Company ...
(Date:7/30/2014)... SAN DIEGO , July 30, 2014   ... that designs and develops novel diagnostics to personalize and ... the appoint of Gregory T. Lucier as ... previously chairman and CEO of Life Technologies (formerly Invitrogen). ... expertise as Epic commercializes its circulating rare cell analysis ...
Breaking Biology Technology:Wyle Wins NASA's Fully Integrated Lifecycle Mission Support Services Contract 2Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 2Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 3Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 3
... MADISON -- The same chemical reaction that causes iron to ... stress chips away at healthy cells and is a process, ... conditions in humans ranging from Alzheimer,s, heart disease and stroke ... writing in the current edition (Feb. 21, 2008) of the ...
... N.C., Feb. 20 Addrenex,Pharmaceuticals has reached its ... a new drug application (NDA) for its first ... Food and Drug,Administration, Addrenex and its licensing partner ... first half of 2009., Addrenex has moved ...
... SGI Altix, Altix XE Cluster and SGI InfiniteStorage ... Environment for All Stages of Research, SUNNYVALE, ... Annual Lorne Genome Conference -- To create an ... bioinformatics,research, the Malaysia Genomics Institute (MGI) selected SGI ...
Cached Biology Technology:Genetic pathway critical to disease, aging found 2Genetic pathway critical to disease, aging found 3Addrenex Pharmaceuticals Reaches Milestone with Filing of NDA for First Product, CloniBID, to Treat Hypertension 2Malaysia Genome Institute Advances Bioinformatics Research Using SGI Technology 2Malaysia Genome Institute Advances Bioinformatics Research Using SGI Technology 3Malaysia Genome Institute Advances Bioinformatics Research Using SGI Technology 4
(Date:7/30/2014)... Washington, DCToday scientists unveiled the first high-resolution map ... the entire country of Per. The new and ... a sea change for future market-based carbon economies. ... extremely high ecological diversity and it provides the ... degradation for conservation, land use, and enforcement purposes. ...
(Date:7/29/2014)... in the University of Bristol,s Nutrition and Behaviour Unit ... into account when planning meals. , The research, to ... Ingestive Behavior Conference (SSIB 2014) in Seattle, USA this ... do. , The team was led by Professor Jeff ... Psychology. , As part of a Biotechnology and Biological ...
(Date:7/29/2014)... warms and sea ice retreats, the North is changing. ... open water which is predicted to extend across the ... Storms thus have the potential to create Arctic swell ... unpredictable element to the region. , A University of Washington ... middle of the Arctic Ocean, and detected house-sized waves ...
Breaking Biology News(10 mins):Peru's carbon quantified: Economic and conservation boon 2Peru's carbon quantified: Economic and conservation boon 3Huge waves measured for first time in Arctic Ocean 2Huge waves measured for first time in Arctic Ocean 3
... GEOLOGY ends 2012 with 23 new articles spanning ... Naica Cave, Mexico; Diamantina, Brazil; the Galpagos hotspot; China; ... central West Greenland; the California arc; the Pacific Ring ... Sierra Nevada; Spain; New Zealand; Turkey; Connecticut, USA; and ...
... the extinct giant piranha, or megapiranha, have the most ... body size is taken into account, finds researchers in ... The research paper, Mega-Bites: Extreme jaw forces of living ... which allows them to attack and bite chunks out ...
... RICHLAND, Wash. Pacific Northwest National Laboratory has been ... large amounts of renewable energy until it,s needed, fight ... to the marketplace. The Federal Laboratory Consortium announced ... Richland is receiving three 2013 Excellence in Technology Transfer ...
Cached Biology News:GEOLOGY returns to Naica Cave, Mexico, and extends its reach to Mercury 2GEOLOGY returns to Naica Cave, Mexico, and extends its reach to Mercury 3GEOLOGY returns to Naica Cave, Mexico, and extends its reach to Mercury 4GEOLOGY returns to Naica Cave, Mexico, and extends its reach to Mercury 5GEOLOGY returns to Naica Cave, Mexico, and extends its reach to Mercury 6GEOLOGY returns to Naica Cave, Mexico, and extends its reach to Mercury 7GEOLOGY returns to Naica Cave, Mexico, and extends its reach to Mercury 8GEOLOGY returns to Naica Cave, Mexico, and extends its reach to Mercury 9GEOLOGY returns to Naica Cave, Mexico, and extends its reach to Mercury 10GEOLOGY returns to Naica Cave, Mexico, and extends its reach to Mercury 11GEOLOGY returns to Naica Cave, Mexico, and extends its reach to Mercury 12GEOLOGY returns to Naica Cave, Mexico, and extends its reach to Mercury 13GEOLOGY returns to Naica Cave, Mexico, and extends its reach to Mercury 14GEOLOGY returns to Naica Cave, Mexico, and extends its reach to Mercury 15GEOLOGY returns to Naica Cave, Mexico, and extends its reach to Mercury 16GEOLOGY returns to Naica Cave, Mexico, and extends its reach to Mercury 17GEOLOGY returns to Naica Cave, Mexico, and extends its reach to Mercury 18GEOLOGY returns to Naica Cave, Mexico, and extends its reach to Mercury 19GEOLOGY returns to Naica Cave, Mexico, and extends its reach to Mercury 20Black piranha, megapiranha have most powerful bites of fish living or extinct, finds GW researcher 2PNNL recognized for transferring innovations to the marketplace 2PNNL recognized for transferring innovations to the marketplace 3
... commonly used technique for studying protein function ... on SDS-PAGE and transferred to a membrane ... are probed with specific antibodies. Unlike nucleic ... Southern and Northern blots, it has been ...
... System, Basic Package Superior Protein Detection ... The ProXPRESS 2D Proteomic Imaging System is ... both proteomic and general life science research ... the use of all dyes in the ...
... our Regulatory Edition of Molecular Imaging (MI) ... for life science research and drug discovery ... with U.S. Food and Drug Administrations Code ... Electronic Records; Electronic Signatures [21 CFR Part ...
... OPA1-01009, OPEP-01009 is a 16 amino acid (amino acids 3-18) ... (DFF). The sequence of this peptide is (amino to ... S - V - K - L - R - ... R - K(18). This peptide may be used ...
Biology Products: